Abide Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Abide Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10691
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Abide Therapeutics Inc (Abide) is a clinical development stage company that discovers and develops therapeutic potential of serine hydrolases to transform the lives of patients with serious unmet medical needs. The company’s pipeline include ABX-1431, a first-in-class inhibitor of the serine hydrolase monoacylglycerol lipase (MGLL) that is designed to treat a wide range of CNS diseases by regulating neurotransmitter release. It offers platform such as proprietary chemical library, which is designed to interact with serine hydrolases and chemoproteomics. The company develops therapies for central and peripheral inflammation, chronic and neuropathic pain and metabolic disease. Abide is headquartered in San Diego, California, the US.

Abide Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Abide Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Abide Therapeutics Raises USD6.6 Million in Series A Financing 10
Partnerships 11
Abide Therapeutics Enters Into Drug Discovery Agreement With Celgene 11
Abide Therapeutics Enters Into Co-Development Agreement With Merck 12
Licensing Agreements 13
Celgene Enters into Licensing Agreement with Abide Therapeutics 13
Abide Therapeutics Inc – Key Competitors 14
Abide Therapeutics Inc – Key Employees 15
Abide Therapeutics Inc – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Corporate Communications 17
Apr 04, 2018: Abide Therapeutics Appoints Thomas C. Sudhof to Board of Directors 17
Sep 18, 2017: Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Abide Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Abide Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Abide Therapeutics Raises USD6.6 Million in Series A Financing 10
Abide Therapeutics Enters Into Drug Discovery Agreement With Celgene 11
Abide Therapeutics Enters Into Co-Development Agreement With Merck 12
Celgene Enters into Licensing Agreement with Abide Therapeutics 13
Abide Therapeutics Inc, Key Competitors 14
Abide Therapeutics Inc, Key Employees 15
Abide Therapeutics Inc, Other Locations 16

List of Figures
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Abide Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Abide Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SynergEyes Inc-医療機器分野:企業M&A・提携分析
    Summary SynergEyes Inc (SynergEyes) is a medical device company that offers contact lenses. The company offers hybrid contact lenses to transform vision for patients with astigmatism, presbyopia, presbyopia, myopia, hyperopia, keratoconus, and other eye conditions. It provides ultrahealth hybrid len …
  • Marquard & Bahls AG:企業の戦略的SWOT分析
    Marquard & Bahls AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • LipimetiX Development Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary LipimetiX Development Inc (LipimetiX), formerly LipimetiX LLC is a biopharmaceutical company that develops drugs to treat refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases. The company develops drugs based on chimeri …
  • Cipla Ltd (CIPLA):企業の財務・戦略的SWOT分析
    Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Ube Industries, Ltd.:企業の戦略・SWOT・財務情報
    Ube Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ube Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Danieli & C. Officine Meccaniche SpA:戦略・SWOT・企業財務分析
    Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report Summary Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Volta River Authority-エネルギー分野:企業M&A・提携分析
    Summary Volta River Authority (VRA) is a state-owned energy utility that generates, transmits, and distributes electricity. The authority produces power from solar, hydro, light crude oil, distillate fuel oil, and heavy fuel oil sources. It procures energy from Takoradi International Company Ltd; an …
  • Stanmore Coal Ltd:企業の戦略・SWOT・財務情報
    Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report Summary Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Lexicon Pharmaceuticals Inc (LXRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program …
  • Norwegian Cruise Line Holdings Ltd. (NCLH):企業の財務・戦略的SWOT分析
    Norwegian Cruise Line Holdings Ltd. (NCLH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Arab Banking Corporation (BSc):企業の戦略・SWOT・財務情報
    Arab Banking Corporation (BSc) - Strategy, SWOT and Corporate Finance Report Summary Arab Banking Corporation (BSc) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Cerenis Therapeutics Holding SA (CEREN):企業の財務・戦略的SWOT分析
    Summary Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic …
  • Holtec International Inc:電力:M&Aディール及び事業提携情報
    Summary Holtec International, Inc. (Holtec) is a diversified energy technology company. It supplies equipment and systems for the nuclear, solar, geothermal and fossil power generation sectors of the energy industry. The company’s products and service portfolio includes advanced technology solutions …
  • HCA Healthcare Inc (HCA)-製薬・医療分野:企業M&A・提携分析
    Summary HCA Healthcare Inc (HCA), formerly known as HCA Holdings Inc, is a health care services company that provides a wide range of services in specialties including internal medicine; general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics. It also offers outpatient and an …
  • Interpace Diagnostics Group Inc (IDXG)-医療機器分野:企業M&A・提携分析
    Summary Interpace Diagnostics Group Inc (Interpace Diagnostics), formerly PDI Inc, is a developer of molecular diagnostics tests. The company offers PancraGen, a DNA based molecular test that aids in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its pathfinder platform; a …
  • INC Research LLC-製薬・医療分野:企業M&A・提携分析
    Summary INC Research LLC (INC Research), a subsidiary of INC Research Holdings Inc is a healthcare services provider that offers contract research services. The organization provides phase I to IV clinical development services. Its services include study start-up, INC pressure test, INC patient elig …
  • Energy Resources Conservation and Development Commission:企業の戦略的SWOT分析
    Energy Resources Conservation and Development Commission - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key …
  • GAIL (India) Limited:企業の戦略・SWOT・財務情報
    GAIL (India) Limited - Strategy, SWOT and Corporate Finance Report Summary GAIL (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Microsoft Corporation (MSFT):企業の財務・戦略的SWOT分析
    Microsoft Corporation (MSFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Sorgenia SpA:電力:M&Aディール及び事業提携情報
    Summary Sorgenia SpA (Sorgenia) is an electricity generator and energy utilities company. The company operates in the energy and natural gas sector. It produces, imports, and sells electricity and gas. The company also offers various integrated power saving equipment and services. Sorgenia is a grou …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆